Premium Industrial News
China's CARsgen Joins European Plan for Tumor TherapyChina's CARsgen Joins European Plan for Tumor Therapy
Industry Segment: Pharmaceutical & Biotech | Word Count: 119 Words
BEIJING--November 24, 2021--Researched by Industrial Info Resources (Sugar Land, Texas)--Pharmaceutical company CARsgen Therapeutics Holdings Limited (Xuhui, China) recently joined European Medicines Agency's (EMA) PRIME (Priority Medicine) plan for its CAR-T Therapy product CT041, which is used to treat solid tumors.
This Premium Article can be purchased individually or as part of a subscription
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Lonza Expanding Swiss Microbial Operations
- Japan's Pharma Majors Invest $388 Million in Generic Drug Projects
- Biopharma, Traditional Pharma Face Different Supply-Chain Issues in Pandemi...
- Webinar: How Sulzer's Laser Metal Deposition Technology Can Extend the Serv...
- Almac Plans 1,000 New Pharma Jobs in Northern Ireland
Quick Links
- Home
- About Us
- Contact Us
- For Traders
Global Market Intelligence
- GMI Database Platform
- GMI Platform Tools
- Industry Coverage
- Analytics & Insights
- Advertising
